Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. disease spreading
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Disease Spreading Articles & Analysis

69 news found

CDC Offers Action Items to Reduce Infection Risks in Schools

CDC Offers Action Items to Reduce Infection Risks in Schools

In May, the Centers for Disease Control and Prevention (CDC) announced the release of new guidance for preventing the spread of infections in K-12 schools. The agency shared various everyday actions that schools can take to help keep students healthy by mitigating the spread of infections. The five actions listed by the CDC are: ยท ...

ByCochrane & Associates, LLC


CDC Releases Everyday Actions for Schools to Prevent and Control the Spread of Infections

CDC Releases Everyday Actions for Schools to Prevent and Control the Spread of Infections

The Centers for Disease Control and Prevention (CDC) recently released new guidance for preventing the spread of infections in K-12 schools. The agency has shared various everyday actions that schools can take to help keep students healthy by minimizing the spread of infections. Five of the actions listed by CDC include: ยท ...

ByCochrane & Associates, LLC


World TB Day and Infection Control Resources in New York City to Help Prevent New Cases

World TB Day and Infection Control Resources in New York City to Help Prevent New Cases

TB is caused by a bacterium known as Mycobacterium tuberculosis that typically attacks the lungs, but can also attack other parts of the body. The disease can be spread from a person with the disease of the lungs or throat through the air from one person to another when they cough, sneeze, speak, or sing. ...

ByCochrane & Associates, LLC


Amerigo Scientific Rolls Out Real-Time PCR Kits to Facilitate HAV Research

Amerigo Scientific Rolls Out Real-Time PCR Kits to Facilitate HAV Research

With over 1.4 million cases reported worldwide annually, effective research and diagnostic tools are crucial for combating the spread of this infectious disease. As a leading distributor in the life science industry, Amerigo Scientific provides HAV PCR kits that can greatly enhance the efficiency and accuracy of HAV research. ...

ByAmerigo Scientific


Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. โ€œProstate cancer cases in China have increased significantly in recent years. Compounding that, nearly a third of patients who are newly diagnosed will have metastatic ...

ByBayer AG


Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

โ€œWe are committed to improving prostate cancer care across all stages of the disease and recognize that for patients and their families, quality of life is just as critical as prolonging survival and delaying disease progression. ...

ByBayer AG


Nubeqa approved for additional indication in Japan

Nubeqa approved for additional indication in Japan

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or ...

ByBayer AG


New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

Of 1,305 patients in the full analysis set, 1,005 (77%) had high-volume disease, 912 (70%) had high-risk disease, 300 (23%) had low-volume disease, and 393 (30%) had low-risk disease. ...

ByBayer AG


CHMP recommends Bayerโ€™s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommends Bayerโ€™s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

This recommendation is another step in our mission to redefine what it means to live with prostate cancer across various stages of the disease.โ€ โ€œDespite significant advances, for many men with mHSPC, disease progression and the onset of debilitating symptoms remain commonplace. ...

ByBayer AG


7 December 2022 - FDA/CDC highlight need for infection preventions

7 December 2022 - FDA/CDC highlight need for infection preventions

Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...

ByDestiny Pharma plc


Longenesis and Dante Genomics Partner to Make Personalised Medicine More Accessible Across Europe

Longenesis and Dante Genomics Partner to Make Personalised Medicine More Accessible Across Europe

WGS and Danteโ€™s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, ...

ByLongenesis


New ARASENS data reinforce strong tolerability profile of darolutamide plus ADT and docetaxel without compromising quality of life for patients with mHSPC

New ARASENS data reinforce strong tolerability profile of darolutamide plus ADT and docetaxel without compromising quality of life for patients with mHSPC

โ€ Additionally, treatment with darolutamide plus ADT and docetaxel showed a trend toward delaying time to worsening of disease-related physical symptoms and pain in patients with moderate or severe baseline pain and improvement across patient-relevant endpoints compared to ADT plus docetaxel, supporting early treatment intensification with addition of darolutamide. ...

ByBayer AG


U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.5 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or ...

ByBayer AG


Biomedical Company Gedeon Richter Partners with Health Education Platform Skrinings to Deliver Global, No-Cost Contraceptive Education

Biomedical Company Gedeon Richter Partners with Health Education Platform Skrinings to Deliver Global, No-Cost Contraceptive Education

By educating more individuals and collecting real-world data, skrinings.lv is actively contributing to decreasing unwanted pregnancies, lowering the spread of sexually transmitted diseases and helping women take control of their reproductive health. ...

ByLongenesis


U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)

U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)

โ€œBayer remains dedicated to addressing unmet needs in prostate cancer treatment for various stages of the disease,โ€ said Christine Roth, Member of the Executive Committee of Bayerโ€™s Pharmaceutical Division and Head of the Oncology SBU at Bayer. ...

ByBayer AG


Amerigo Scientific Introduces the Launch of Polystreptavidin 350

Amerigo Scientific Introduces the Launch of Polystreptavidin 350

Diagnosis is a key enabler of universal health coverage and the first line of defense against the spread of many diseases. From rapid treatment and combating antimicrobial resistance, to providing personalized medicine, the need for clinical diagnostics, especially in vitro diagnostics, continues to expand. ...

ByAmerigo Scientific


World TB Day and Preventing New Cases in Healthcare Facilities and Correctional Institutions in Puerto Rico

World TB Day and Preventing New Cases in Healthcare Facilities and Correctional Institutions in Puerto Rico

Robert Koch announced his discovery of Mycobacterium tuberculosis, the cause of tuberculosis (TB), back in 1882. The Centers for Disease Control and Prevention (CDC) describes World TB Day as a time to educate the public about the impact of TB around the world. It is also a day for health professionals to share successes in prevention and control, while also raising awareness of ...

ByCochrane & Associates, LLC


Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

โ€œMetastatic prostate cancer is a uniformly fatal disease and despite progress in recent years, only 30% of these men will survive beyond five years. ...

ByBayer AG


Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.(1) At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse when the disease will metastasize or ...

ByBayer AG


Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses

Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses

Testing is the core component of a robust model in preventing the spread of infectious disease. With these resources and testing components in place, we're able to make data-driven decisions and policies to support the health and safety of our students and community." ...

ByThermo Fisher Scientific

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT